

**ASX Release – Alesco Corporation Limited (“ALS”)**

---

**ALESCO COMPLETES THE SALE OF ITS SCIENTIFIC & MEDICAL DIVISION**

---

Date: 30 April 2009

Release: 30 April 2009

---

Alesco Corporation Limited (**Alesco**) confirmed that today it has completed the sale of its Scientific & Medical division (**Biolab**) to Thermo Fisher Scientific Inc for \$175 million.

As previously announced, the profit on sale before tax (but after transaction costs) is estimated to be approximately \$65 million.<sup>1</sup>

Alesco retains an attractive and diverse portfolio of leading industrial brands with a significant focus on the renovations and residential sectors as well as the water and infrastructure sectors.

“This sale substantially strengthens Alesco’s financial position and will ensure Alesco is well positioned to benefit from the recovery of the residential housing cycle and the overall economy,” Alesco CEO Mr Justin Ryan said.

As previously announced it is the board’s intention to resume paying dividends. However a decision on the quantum of the FY09 final dividend will not be made until the company’s full-year FY09 audited results are finalised and will be considered in light of the business outlook at that time and prevailing external conditions.

**FOR FURTHER INFORMATION:**

**Mr. Justin Ryan**  
Chief Executive Officer  
Tel: 61 2 9248 2022

**Mr. Neil Thompson**  
Finance Director  
Tel: 61 2 9248 2022

\* \* \* \* \*

Alesco manages a portfolio of leading industrial brands. It operates through four divisions Construction & Mining, Functional & Decorative Products, Garage Doors & Openers and Water Products and Services and services a large and diverse range of customers in a variety of renovations and residential building and water and infrastructure market sectors in Australia and New Zealand. It will have on a pro-forma basis approximately \$900 million in annual revenue and approximately 2,500 employees. For more information on Alesco visit [www.alesco.com.au](http://www.alesco.com.au)

---

<sup>1</sup> Net profit on sale will be treated as a significant item at year end

**asx release**

---